DDInter1191 DDInter1376
Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Methylprednisolone {u} (Compound) resembles {v} (Compound) Halobetasol Propionate
Methylprednisolone {u} (Compound) resembles {v} (Compound) Testolactone
Methylprednisolone {u} (Compound) treats {v} (Disease) rheumatoid arthritis
Methylprednisolone {u} (Compound) binds {v} (Gene) CYP3A4
Methylprednisolone {u} (Compound) upregulates {v} (Gene) ZFP36
Methylprednisolone {u} (Compound) palliates {v} (Disease) hematologic cancer
Methylprednisolone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Methylprednisolone {u} (Compound) downregulates {v} (Gene) FOSL1
Methylprednisolone {u} (Compound) causes {v} (Side Effect) Diplegia
Methylprednisolone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Isoniazid
Methylprednisolone (Compound) resembles Halobetasol Propionate (Compound)
Methylprednisolone (Compound) resembles Testolactone (Compound)
Methylprednisolone (Compound) treats rheumatoid arthritis (Disease)
Methylprednisolone (Compound) binds CYP3A4 (Gene)
Methylprednisolone (Compound) upregulates ZFP36 (Gene)
Methylprednisolone (Compound) palliates hematologic cancer (Disease)
Methylprednisolone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Methylprednisolone (Compound) downregulates FOSL1 (Gene)
Methylprednisolone (Compound) causes Diplegia (Side Effect)
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Isoniazid